Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

• Status: Completed
• Trial end date: 2018-09-27
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Denosumab

Criteria

Inclusion Criteria:

• post menopausal osteoporosis women in whom a decision has been made to treat with Prolia in the last 4 weeks

• received their first prescription of Prolia in the last 4 weeks

• patient has provided informed consent before enrolling in the study

Exclusion Criteria:

• patients participating in ongoing or previous Denosumab clinical trials